Dr. Janni on the Benefits of Targeted Therapies for HER2-Positive Breast Cancer

Wolfgang Janni, MD, PhD
Published: Tuesday, Apr 04, 2017



Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 


Wolfgang Janni, MD, PhD, University of Ulm, discusses the benefits of HER2-targeted therapies for patients with all stages of HER2-positive breast cancer.

According to Janni, the benefits of HER2-targeted therapies in breast cancer outweigh the adverse events that patients experience.

The most common adverse events that are associated with HER2-targeted treatments include cardiotoxicity and diarrhea, states Janni.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Leveraging New Evidence in the Context of Evolving Early-Stage Treatment Standards in HER2-Positive Breast CancerJan 30, 20181.5
14th Annual School of Breast Oncology® OnlineFeb 10, 201825
Publication Bottom Border
Border Publication
x